Development of skin hypopigmentation in a patient with metastatic papillary carcinoma thyroid treated with Sorafenib

BMC Endocrine Disorders

Najmul Islam¹  Mubasher Ikram²  Ali Asghar¹  Syed Zubair Hussain¹ 

[1]Department of Medicine, Section of Endocrinology, Aga Khan University Hospital, Stadium Road, P.O. Box 3500, Karachi 74800 Pakistan

[2]Department of Surgery, Section of Otorhinolaryngology, Aga Khan University Hospital, Stadium Road, P.O. Box 3500, Karachi 74800 Pakistan

关键词: Hypopigmentation;    Sorafenib;    Thyroid Carcinoma;   

Others  :  1085754
DOI  :  10.1186/1472-6823-13-29

 received in 2013-04-22, accepted in 2013-08-08,  发布年份 2013

【 摘 要 】

Background

Sorafenib can be considered as the effective option of treatment in patients with metastatic radioiodine refractory differentiated thyroid cancers. The cutaneous manifestations of Sorafenib include rash, desquamation, hand foot skin reactions, pruritus, alopecia and erythema. We report the first case of hypopigmentation related to sorafenib therapy.

Case presentation

We report the case of a middle aged gentleman with metastatic papillary carcinoma of thyroid diagnosed in 2005. He was managed with total thyroidectomy, radioactive iodine and TSH suppressive therapy. Despite receiving radioactive iodine 530 mci cumulative dose, patient had persistant disease with lung metastasis. Therefore a TKI, sorafenib, was started. He developed hypopigmentation of the skin more prominent on face six weeks after starting sorafenib treatment.He also developed diarrhea, desquamation of hands and feet, hair loss over scalp, eye brows and moustache. Sorafenib treatment was discontinued. His diarrhea stopped in one week and after four weeks his skin became normalized whereas he regained his hairs in six weeks.

Conclusion

To our knowledge, hypopigmentation in our patient appears to be the first reported of its kind in the literature to date. Sorafenib is used in Renal cell carcinoma, Hepatcellular carcinoma and radioactive iodine refractory thyroid carcinoma therefore it is very important to be aware of hypopigmentation as a potential side effect for both physicians and patients.

【 授权许可】

   
2013 Hussain et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 2007, 57(1):43-66.
• [2]American cancer society: Cancer facts and figures 2010. Atlanta: American cancer society; 2010.
• [3]Shaha AR, Shah JP, Loree TR: Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. Am J Surg 1996, 172(6):692-694.
• [4]Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA: Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab 1988, 67(3):501-508.
• [5]Shoup M, Stojadinovic A, Nissan A, Ghossein RA, Freedman S, Brennan MF, Shah JP, Shaha AR: Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg 2003, 197(2):191-197.
• [6]Nikiforov YE: Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 2008, 21(Suppl 2):S37-S43.
• [7]Tuttle RM, Fleisher M, Francis GL, Robbins RJ: Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J Clin Endocrinol Metab 2002, 87(4):1737-1742.
• [8]Robert C, Mateus C, Spatz A, Wechsler J, Escudier B: Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009, 60(2):299-305.
• [9]Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, et al.: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24(26):4293-4300.
• [10]Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356(2):125-134.
• [11]Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit JW, Kapiteijn E: Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol 2012, 167(5):643-650.
• [12]Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O’Dwyer PJ, et al.: Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008, 26(29):4714-4719.
• [13]Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, et al.: Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009, 27(10):1675-1684.
• [14]Brose MS, et al.: ‘Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the phase III DECISION trial’. ASCO 2013. Abstract 4 MedPage Today, June 04, 2013.
• [15]Autier J, Escudier B, Wechsler J, Spatz A, Robert C: Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008, 144(7):886-892.
• [16]Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK: Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009, 161(5):1045-1051.
• [17]Bracarda S, Ruggeri EM, Monti M, Merlano M, D’Angelo A, Ferrau F, Cortesi E, Santoro A: Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib working group. Crit Rev Oncol Hematol 2012, 82(3):378-386.